Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Urogen Pharma Ltd URGN

Healthcare Biotechnology
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).


NDAQ:URGN - Post by User

Urogen Pharma Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(250)
•••
Post by whytestockson Jun 14, 2024 11:30am
48 Views
Post# 36089237

URGN Price Target Alert: $40.00. Issued by Oppenheimer

URGN Price Target Alert: $40.00. Issued by Oppenheimer
Breaking News: $URGN URGN Price Target Alert: $40.00. Issued by Oppenheimer2024-06-14 09:00:10 ET Leland Gershell from Oppenheimer issued a price target of $40.00 for URGN on 2024-06-14 07:43:00. The adjusted price target was set to $40.00. At the time of the announcement, URGN was trading at $17.5. The overall price target consensus is at $38....URGN - URGN Price Target Alert: $40.00. Issued by Oppenheimer

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities